

Pharmaceutical Trading Company Ltd representing Hospira* in Cyprus - 2016 Report
***Hospira is a Pfizer company**

Date of publication 20/06/2016

	Full Name (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered (Art. 3)	Country of Principal Practice (Schedule 1)	Principal Practice Address (Art. 3)	Unique country identifier OPTIONAL (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a) (EUR)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		TOTAL OPTIONAL (EUR)
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event (EUR)	Registration Fees (EUR)	Travel & Accommodation (EUR)	Fees (EUR)	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract (EUR)	
						N/A	N/A					
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>											
	Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A	360,00	1.400,00	0,00	0,00	1.760,00
	Number of Recipients in aggregate disclosure					N/A	N/A	2	2	N/A	N/A	N/A
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					N/A	N/A	100,00%	100,00%	N/A	N/A	N/A
	Cyprus Society of Dermatology and Venereology organised by CUBIX minds	Nicosia	CYPRUS	Themistokil Thervi 22, 1066 Nicosia	NA	0,00	3.451,00	0,00	0,00	0,00	0,00	3.451,00
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>											
	Aggregate amount attributable to transfers of value to such Recipients					0,00	0,00	0,00	0,00	0,00	0,00	0
	Number of Recipients in aggregate disclosure					0	0	0	0	0	0	0
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					0,00%	0,00%	0,00%	0,00%	0,00%	0,00%	N/A
R&D	AGGREGATE DISCLOSURE											
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											
	0,00											

Accuracy of the data presented in this report is confirmed by Mr. Nicolas Karoullas, Managing Director of Pharmaceutical Trading Company Ltd